{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:02:34Z","timestamp":1782831754517,"version":"3.54.5"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Jiangsu Pharmaceutical Association-Shiyao Hospital Pharmaceutical Research Fund","award":["SY202306"],"award-info":[{"award-number":["SY202306"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Hypofibrinogenaemia is a serious adverse reaction associated with tigecycline (TGC) therapy and may lead to the discontinuation of the treatment. This study aimed to explore the relevant factors of TGC-induced hypofibrinogenaemia and determine the thresholds of serum concentration as a predictive indicator of TGC-induced hypofibrinogenaemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective single-centre study was conducted on patients with severe infection who were treated with TGC. Clinical data and serum concentration parameters were extracted from the electronic medical records of these patients. Patients were divided into the hypofibrinogenaemia group (&amp;lt; 2.0\u2005g\/L) and the normal fibrinogen group (\u2265 2.0\u2005g\/L) in order to evaluate risk factors associated with TGC-induced hypofibrinogenaemia. Logistic regression analysis and receiver operating characteristic curves were utilized to identify the risk factors associated with TGC-induced hypofibrinogenaemia and to establish plasma concentration thresholds as predictive indicators.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 114 patients were enrolled in this study, with 59.6% experiencing hypofibrinogenaemia. The multivariate regression analysis indicated that baseline fibrinogen level, trough concentration (Cmin), peak concentration (Cmax), the concentration at 6\u2005h after the dosing (C6h) and the area under the concentration\u2013time curve over a 24-h period (AUC0\u201324) were significantly associated with hypofibrinogenaemia (P\u200a&amp;lt;\u200a0.05). Furthermore, it was found that AUC0\u201324 is the optimal predictor of TGC-induced hypofibrinogenaemia. The optimal cut-off for the AUC0\u201324 of TGC in ICU patients was determined to be 17.03\u2005mg\u2005h\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TGC exposure is highly predictive of TGC-induced hypofibrinogenaemia. We recommend closely monitoring plasma concentrations of TGC in patients to ensure patient efficacy and safety.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae396","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T12:10:58Z","timestamp":1730981458000},"page":"200-208","source":"Crossref","is-referenced-by-count":5,"title":["Serum concentration threshold and risk factors of tigecycline-induced hypofibrinogenaemia in critically ill patients"],"prefix":"10.1093","volume":"80","author":[{"given":"Mengxue","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Zhongda Hospital, Southeast University , Nanjing 210009 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongda Hospital, Southeast University , Nanjing 210009 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoqiu","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongda Hospital, Southeast University , Nanjing 210009 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongda Hospital, Southeast University , Nanjing 210009 ,","place":["China"]},{"name":"Office of Clinical Trial Institution, Zhongda Hospital, Southeast University , Nanjing 210009 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongda Hospital, Southeast University , Nanjing 210009 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"2025010309482773800_dkae396-B1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0194-5998(97)80284-7","article-title":"The antibiotic resistance crisis: part 1: causes and threats","volume":"40","author":"Ventola","year":"2015","journal-title":"P T"},{"key":"2025010309482773800_dkae396-B2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1592\/phco.26.8.1099","article-title":"Tigecycline: first of a new class of antimicrobial agents","volume":"26","author":"Rose","year":"2006","journal-title":"Pharmacotherapy"},{"key":"2025010309482773800_dkae396-B3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1469-0691.2006.01621.x","article-title":"Tigecycline: in-vitro performance as a predictor of clinical efficacy","volume":"13","author":"Hawkey","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"2025010309482773800_dkae396-B4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1086\/431674","article-title":"The pharmacokinetic and pharmacodynamic profile of tigecycline","volume":"41","author":"Meagher","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2025010309482773800_dkae396-B5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jgar.2021.04.006","article-title":"Dose optimisation based on pharmacokinetic\/pharmacodynamic target of tigecycline","volume":"25","author":"Leng","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2025010309482773800_dkae396-B6","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2165\/00003495-200565100-00002","article-title":"Tigecycline: a novel glycylcycline","volume":"65","author":"Rubinstein","year":"2005","journal-title":"Drugs"},{"key":"2025010309482773800_dkae396-B7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1473-3099(11)70177-3","article-title":"Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis","volume":"11","author":"Tasina","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2025010309482773800_dkae396-B8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2015.08.009","article-title":"Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta analysis of RCTs","volume":"39","author":"Shen","year":"2015","journal-title":"Int J Infect Dis"},{"key":"2025010309482773800_dkae396-B9","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/17425255.2011.623126","article-title":"Pharmacokinetic and pharmacodynamic evaluation of tigecycline","volume":"7","author":"Giamarellou","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025010309482773800_dkae396-B10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv Ther"},{"key":"2025010309482773800_dkae396-B11","doi-asserted-by":"publisher","first-page":"e17091","DOI":"10.1097\/MD.0000000000017091","article-title":"Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: a meta-analysis","volume":"98","author":"Gong","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025010309482773800_dkae396-B12","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review","volume":"41","author":"Yaghoubi","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025010309482773800_dkae396-B13","doi-asserted-by":"publisher","first-page":"e22638","DOI":"10.1097\/MD.0000000000022638","article-title":"Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature","volume":"99","author":"Fan","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2025010309482773800_dkae396-B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.idcr.2018.01.003","article-title":"Tigecycline-induced hypofibrinogenemia: a case report and review of the literature","volume":"12","author":"Wu","year":"2018","journal-title":"IDCases"},{"key":"2025010309482773800_dkae396-B15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4274\/tjh.2017.0310","article-title":"A lesser known side effect of tigecycline: hypofibrinogenemia","volume":"35","author":"Duran","year":"2018","journal-title":"Turk J Haematol"},{"key":"2025010309482773800_dkae396-B16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00277-010-0911-7","article-title":"Severe coagulation disorder with hypofbrinogenemia associated with the use of tigecycline","volume":"89","author":"Pieringer","year":"2010","journal-title":"Ann Hematol"},{"key":"2025010309482773800_dkae396-B17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijantimicag.2014.07.014","article-title":"High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections","volume":"45","author":"Routsi","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2025010309482773800_dkae396-B18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12959-022-00369-z","article-title":"Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database","volume":"20","author":"Guo","year":"2022","journal-title":"Thromb J"},{"key":"2025010309482773800_dkae396-B19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2025010309482773800_dkae396-B20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijid.2013.09.008","article-title":"Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic\/pharmacodynamic analysis of tigecycline by Monte Carlo simulation","volume":"18","author":"Xie","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2025010309482773800_dkae396-B21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1128\/AAC.00277-10","article-title":"Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia","volume":"56","author":"Rubino","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010309482773800_dkae396-B22","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/jcpt.13250","article-title":"Risk factors for tigecycline-associated hypofibrinogenaemia","volume":"45","author":"Zhang","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"2025010309482773800_dkae396-B23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00228-020-02860-w","article-title":"Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients","volume":"76","author":"Hu","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2025010309482773800_dkae396-B24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.5966\/sctm.2015-0381","article-title":"Concise review: bridging the Gap: novel neuroregenerative and neuroprotective strategies in spinal cord injury","volume":"5","author":"Ahuja","year":"2016","journal-title":"Stem Cells Transl Med"},{"key":"2025010309482773800_dkae396-B25","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1111\/jth.14216","article-title":"Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH","volume":"16","author":"Casini","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2025010309482773800_dkae396-B26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3109\/23744235.2015.1043942","article-title":"Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder","volume":"47","author":"Sabanis","year":"2015","journal-title":"Infect Dis(Lond)"},{"key":"2025010309482773800_dkae396-B27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1046\/j.1365-2141.1996.d01-1731.x","article-title":"Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13","volume":"93","author":"Vasse","year":"1996","journal-title":"Br J Haematol"},{"key":"2025010309482773800_dkae396-B28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3109\/08923970902838672","article-title":"Tigecycline attenuates staphylococcal superantigeninduced T-cell proliferation and production of cytokines and chemokines","volume":"31","author":"Saliba","year":"2009","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2025010309482773800_dkae396-B29","doi-asserted-by":"publisher","first-page":"761167","DOI":"10.3389\/fphar.2021.761167","article-title":"Real-world data of tigecycline-associated drug-induced liver injury among patients in China: a 3-year retrospective study as assessed by the updated RUCAM","volume":"12","author":"Shi","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025010309482773800_dkae396-B30","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/jcph.2099","article-title":"Risk factors for tigecycline-associated hepatotoxicity in patients in the intensive care units of 2 tertiary hospitals: a retrospective study","volume":"62","author":"Jiang","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"2025010309482773800_dkae396-B31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/TCRM.S302850","article-title":"Risk factors for tigecycline-induced hypofibrinogenemia","volume":"17","author":"Liu","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"2025010309482773800_dkae396-B32","doi-asserted-by":"publisher","first-page":"943674","DOI":"10.3389\/fphar.2022.943674","article-title":"Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: a multicenter retrospective study in China","volume":"13","author":"Leng","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025010309482773800_dkae396-B33","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1177\/0091270011416938","article-title":"Tigecycline pharmacokinetics in subjects with various degrees of renal function","volume":"52","author":"Korth-Bradley","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"2025010309482773800_dkae396-B34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/jcph.236","article-title":"Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects","volume":"54","author":"Yamashita","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2025010309482773800_dkae396-B35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/FTD.0000000000000784","article-title":"Safety and efficacy of tigecycline in intensive care unit patients based on therapeutic drug monitoring","volume":"42","author":"Fan","year":"2020","journal-title":"Ther Drug Monit"},{"key":"2025010309482773800_dkae396-B36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijid.2022.08.014","article-title":"Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: a retrospective cohort study","volume":"123","author":"Yang","year":"2022","journal-title":"Int J Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/1\/200\/60475919\/dkae396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/1\/200\/60475919\/dkae396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:48:50Z","timestamp":1735897730000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/1\/200\/7884026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,7]]},"published-print":{"date-parts":[[2025,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae396","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,11,7]]}}}